Home
/
Unlisted Shares
/
Sigrid Therapeutics

Sigrid Therapeutics Share

20.6
SEK
Share price at last known new issue
(
11/2023
)
477000000
SEK
Valuation at last known new issue
(
11/2023
)

Overview

Sigrid Therapeutics is a Swedish clinical biotechnology company developing innovative solutions to prevent and treat lifestyle-related diseases. The company was founded in 2014 by Prof. Tore Bengtsson and Sana Alajmovic with the vision to change the way we manage modern chronic diseases. Their technology, SiPore®, consists of precision-engineered mesoporous silica particles that act in the gut to improve blood sugar control in a safe and effective way. The lead product, SiPore21®, is an oral medical device in clinical development, intended to improve metabolic function in people with prediabetes and new-onset type 2 diabetes. Sigrid Therapeutics is headquartered in Stockholm and is part of Karolinska Innovation's incubator program for promising life science startups in Sweden.

Name
Sigrid Therapeutics
Country
Sweden
Sector
Healthcare
Website
https://www.sigridthx.com/
CEO
Sana Alajmovic
Chairman of the board
Mattias Ankarberg
Number of employees
13
Price per share*
20.6
SEK
Valuation*
477000000
SEK
*The information is based on estimates of the latest rights issue and may be updated.
Healthcare
Biotech
Healthcare Technology
Pharmaceuticals

Sigrid Therapeutics new issues and valuation

If data cannot be obtained from the Swedish Companies Registration Office, the information is based on estimates and may be updated. New share issues can give an indication of a company's value, but factors such as market conditions, the company's development and the purpose of the issue can lead to a valuation that does not always accurately reflect the company's actual value.

Latest new issues

Price per share
Post-money valuation
Size
Date
Nyemission
20.6
SEK
477000000
SEK
43900000
SEK
24/11/23
Nyemission
20.6
SEK
422400000
SEK
72400000
SEK
20/7/21
Nyemission
12
SEK
203100000
SEK
3000000
SEK
21/4/20
Nyemission
8.7
SEK
145700000
SEK
15600000
SEK
12/9/19
Nyemission
7.1
SEK
105600000
SEK
30200000
SEK
1/11/18
If data cannot be obtained from the Swedish Companies Registration Office, the information is based on estimates and may be updated. New share issues can give an indication of a company's value, but factors such as market conditions, the company's development and the purpose of the issue can lead to a valuation that does not always accurately reflect the company's actual value.

Status Sigrid Therapeutics

Uppdatering
• Handelsstopp
Just nu sker det ingen handel bolaget. Detta kan bero på en stundande IPO, uppköp eller liknande.  

Buy shares in Sigrid Therapeutics

All orders are indicative. When you click buy or sell and submit an order, you are not committing to a trade. One of our brokers will contact you to confirm the order.
Buy

Sell shares in Sigrid Therapeutics

All orders are indicative. When you click buy or sell and submit an order, you are not committing to a trade. One of our brokers will contact you to confirm the order. Learn more about selling shares on Accumeo.
Sell
If you have any questions about buying or selling shares in unlisted companies, please do not hesitate to contact us at Accumeo..

Frequently asked Sigrid Therapeutics

Is Sigrid Therapeutics listed on a stock exchange?
Can I buy shares in unlisted companies like Sigrid Therapeutics?
Can I sell shares in unlisted companies like Sigrid Therapeutics?
What is the value of Sigrid Therapeutics?
Can institutional investors buy and sell shares on the private market?

Nyheter

No items found.

Similar companies as Sigrid Therapeutics

Meds

Sector
Retail
Geography
Sweden

Doktor.se

Sector
MedTech
Geography
Sweden

Blykalla

Sector
Energy
Geography
Sweden

Mindler

Sector
Consumer & Lifestyle
Geography
Sweden
Got any further questions?
Don't hesitate to contact us.
Buy & Sell
Overview
Companies
More
Getting started
Legal
Terms & Conditions
Risks
Complaints
Information
FAQ
Contact
Legal
None of the information displayed on or downloadable from www.accumeo.com (“the website”) constitutes a recommendation, offer, or solicitation to buy or sell any securities, nor an offer to provide investment advice or investment services. Representatives of Accumeo AB do not provide recommendations or advice regarding the merits or suitability of any particular investment or transaction, do not assist in the valuation of any security or investment, and do not offer legal, tax, or transactional advisory services.

Investments in shares, particularly in private companies, involve significant risks and are not suitable for all investors. These investments should be considered long-term and may result in the loss of your entire investment. Shares in private companies can be highly illiquid, and there is no guarantee that a sale will be possible. Investors are solely responsible for conducting thorough due diligence and obtaining independent advice before making any investment decisions. This includes a careful assessment of the company’s financial position and relevant legal considerations.Investments in private companies are only appropriate for investors with a high tolerance for risk and who do not require quick liquidity. Conflicts of interest, whether inherent, actual, or potential, may exist between you and Accumeo AB.

Investments made under Regulation (EU) 2020/1503 of the European Parliament and of the Council are not protected by the deposit guarantee schemes established under Directive 2014/49/EU (the Deposit Guarantee Schemes Directive) or by the investor compensation schemes established under Directive 97/9/EC (the Investor Compensation Schemes Directive).

Accumeo is a tied agent of Aqurat Fondkommission AB, a Swedish securities company authorized by the Swedish Financial Supervisory Authority (Finansinspektionen). Click here to read more.

By using the website and its services, you confirm that you have read, understood, and agree to Accumeo’s Terms of Use and Privacy Policy.
© Accumeo AB 2025